Literature DB >> 18524798

Tachykinins in endocrine tumors and the carcinoid syndrome.

Janet L Cunningham1, Eva T Janson, Smriti Agarwal, Lars Grimelius, Mats Stridsberg.   

Abstract

OBJECTIVE: A new antibody, active against the common tachykinin (TK) C-terminal, was used to study TK expression in patients with endocrine tumors and a possible association between plasma-TK levels and symptoms of diarrhea and flush in patients with metastasizing ileocecal serotonin-producing carcinoid tumors (MSPCs).
METHOD: TK, serotonin and chromogranin A (CgA) immunoreactivity (IR) was studied by immunohistochemistry in tissue samples from 33 midgut carcinoids and 72 other endocrine tumors. Circulating TK (P-TK) and urinary-5 hydroxyindoleacetic acid (U-5HIAA) concentrations were measured in 42 patients with MSPCs before treatment and related to symptoms in patients with the carcinoid syndrome. Circulating CgA concentrations were also measured in 39 out of the 42 patients.
RESULTS: All MSPCs displayed serotonin and strong TK expression. TK-IR was also seen in all serotonin-producing lung and appendix carcinoids. None of the other tumors examined contained TK-IR cells. Concentrations of P-TK, P-CgA, and U-5HIAA were elevated in patients experiencing daily episodes of either flush or diarrhea, when compared with patients experiencing occasional or none of these symptoms. In a Spearman partial rank test, the correlation of P-TK with daily diarrhea was independent of both U-5HIAA and CgA levels.
CONCLUSION: We found that TK synthesis occurs in serotonin-IR tumors and that P-TK levels are significantly correlated with symptoms of flush and diarrhea in patients with MSPCs. This is, to our knowledge, the first report demonstrating an independent correlation of P-TKs with carcinoid diarrhea, a symptom that is customarily regarded as serotonin mediated. Further investigations may present opportunities for new therapeutic possibilities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18524798     DOI: 10.1530/EJE-08-0196

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  8 in total

Review 1.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

Review 2.  Carcinoid-syndrome: recent advances, current status and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-02       Impact factor: 3.243

Review 3.  Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.

Authors:  Krystallenia I Alexandraki; Gregory Kaltsas
Journal:  Endocrine       Date:  2011-11-29       Impact factor: 3.633

Review 4.  Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.

Authors:  Giuseppe Fanciulli; Rosaria M Ruggeri; Erika Grossrubatscher; Fabio Lo Calzo; Troy D Wood; Antongiulio Faggiano; Andrea Isidori; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 5.  Workup of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Joseph S Dillon
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

6.  Small bowel carcinoid: a rare cause of bowel obstruction.

Authors:  Gabriel Rodrigues; Raghunath Prabhu; Bharadwaj Ravi
Journal:  BMJ Case Rep       Date:  2013-09-24

7.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059

Review 8.  Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes.

Authors:  Cristina Saavedra; Jorge Barriuso; Mairéad G McNamara; Juan W Valle; Angela Lamarca
Journal:  Cancer Manag Res       Date:  2019-08-08       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.